Publicaciones (60) Publicaciones de Ana Ortega Eslava

2023

  1. Key Factors Associated With Pulmonary Sequelae in the Follow-Up of Critically Ill COVID-19 Patients

    Archivos de Bronconeumologia, Vol. 59, Núm. 4, pp. 205-215

  2. Usefulness of Drug Allergy Alert Systems: Present and Future

    Current Treatment Options in Allergy, Vol. 10, Núm. 4, pp. 413-427

2022

  1. A systematic review of drug allergy alert systems

    International Journal of Medical Informatics, Vol. 159

  2. Allergic Adverse Drug Events after Alert Overrides in Hospitalized Patients

    Journal of Patient Safety, Vol. 18, Núm. 6, pp. 630-636

  3. Major candidate variables to guide personalised treatment with steroids in critically ill patients with COVID-19: CIBERESUCICOVID study

    Intensive Care Medicine, Vol. 48, Núm. 7, pp. 850-864

  4. One-year mortality after ICU admission due to COVID-19 infection

    Intensive Care Medicine

2021

  1. Deploying unsupervised clustering analysis to derive clinical phenotypes and risk factors associated with mortality risk in 2022 critically ill patients with COVID-19 in Spain

    Critical Care, Vol. 25, Núm. 1

  2. Effectiveness of Pharmacokinetic/Pharmacodynamic-Guided Meropenem Treatment in Critically Ill Patients: A Comparative Cohort Study

    Therapeutic drug monitoring, Vol. 43, Núm. 2, pp. 256-263

  3. The importance of being able to compare: Methodologies that result in the best decisions

    Farmacia Hospitalaria

2020

  1. Clinical and economic impact of clinical pharmacist interventions regarding antimicrobials on critically ill patients

    Research in Social and Administrative Pharmacy, Vol. 16, Núm. 9, pp. 1285-1289

  2. Cost-minimization analysis of individually tailored or fixed-scheduled rituximab maintenance therapy for antineutrophil-cytoplasm antibody associated vasculitides

    Farmacia Hospitalaria, Vol. 44, Núm. 2, pp. 46-50

  3. Effectiveness of adjunctive nebulized antibiotics in critically ill patients with respiratory tract infections

    European Journal of Clinical Microbiology and Infectious Diseases, Vol. 39, Núm. 2, pp. 361-368

  4. Evaluar medicamentos también es una actividad clínica

    Farmacia hospitalaria : organo oficial de expresion cientifica de la Sociedad Espanola de Farmacia Hospitalaria, Vol. 45, Núm. 1, pp. 45-47

2018

  1. Corticosteroid treatment in critically ill patients with severe influenza pneumonia: a propensity score matching study

    Intensive Care Medicine, Vol. 44, Núm. 9, pp. 1470-1482

  2. Evidence of clinical and economic impact of pharmacist interventions related to antimicrobials in the hospital setting

    European Journal of Clinical Microbiology and Infectious Diseases, Vol. 37, Núm. 5, pp. 799-822

  3. Influence of sex, age, and weight on levetiracetam pharmacokinetics

    Therapeutic Drug Monitoring, Vol. 40, Núm. 5, pp. 628-634

  4. Limitation of life support techniques at admission to the intensive care unit: A multicenter prospective cohort study

    Journal of Intensive Care, Vol. 6, Núm. 1

2016

  1. Delay in diagnosis of influenza A (H1N1)pdm09 virus infection in critically ill patients and impact on clinical outcome

    Critical Care, Vol. 20, Núm. 1

  2. From qualitative reviews to umbrella reviews

    Umbrella Reviews: Evidence Synthesis with Overviews of Reviews and Meta-Epidemiologic Studies (Springer International Publishing), pp. 21-41

  3. Morphine-induced hearing loss

    American Journal of Health-System Pharmacy, Vol. 73, Núm. 22, pp. 1840-1843